thought call
view jnj good result revenu ep enough
off-set lower expect initi guidanc investor concern near-term
overhang talc litig inde fx headwind may stronger
expect theme like play across biopharma overal
revenu growth guidanc midpoint come prior
estim consensu look weve model declin
pharma segment previous given stronger biosimilar/gener headwind
previous anticip impact us zytiga us remicad
play weve assum pharma growth
previous notabl outlook clearer easier comp multipl label
adopt launch esketamine/erdafitinib henc expect slower organ
pharma growth limit near-term multipl expans dont see mani
meaning pipelin event drive re-rat point near
uptick pharma growth like becom narr lower pt
vs prior maintain equal weight rate
medic device/consum mostli stabl talc remain headwind
pharma continu anchor portfolio initi posit sign effort
turn around consum increment improv medic devic
devic busi see gener stabl trend driven divestitur
forward look improv declin diabet busi divest
expect bolt-on deal devic consum greater interest
investorsthes wide discuss manag consum
unclear whether babi impact heighten talc litig
wasnt expect remain overhang
model updat given perform provid guidanc updat
model decreas revenu estim non-gaap
ep estim come figur detail
quarterli annual ep usd
lower usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
equal weight continu like jnj
continu innov bode well
longer term sentiment could remain neg
given backdrop price pressures/lo
fundament think could
challeng year particularli pharma given multipl
gener launch zytiga revenu growth
expect trough
could use substanti balanc sheet
acquisit fuel faster expect growth
consum margin could improv quickli
medic devic share growth could acceler
pharmaceut pipelin expect may
conserv
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commerci success medic devic
util deceler consum margin
expand quickli could result downward
pressur share price
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
geoff meacham ph kristen stewart cfa herebi certifi view express research report accur reflect
person view subject secur issuer refer research report part compens
directli indirectli relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
